Clinical Trial Update: Barriers and Facilitators of Persistence With Adjuvant Osimertinib

View source ↗

Summary

Clinical trial update examining barriers and facilitators to persistence with adjuvant osimertinib in non-small cell lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• TAGRISSO (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non-small Cell Lung Cancer | Status: NOT_YET_RECRUITING